Cerebrovascular Disease

 

The Practical Cardiology™ Cerebrovascular Disease clinical resource center offers the latest in management of cerebrovascular disease including stroke, transient ischemic attack, aneurysm, and vascular malformation. The fifth most common cause of death in the US, this page will host articles, podcasts, and videos related to prevention and treatment of cerebrovascular disease.

AHA/ASA Release Guidance for Treatment of COVID-19 Vaccine-Related Clotting, Low Platelet Counts

May 03, 2021

The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.

Preventing Stroke: Management of Patients Undergoing Noncardiac and Nonneurological Surgery

April 22, 2021

Dr. Gregory Weiss, a cardiovascular anesthesiologist, breaks down and provides real-world perspective on the application of a recent scientific statement from the AHA and ASA on perioperative management to lower stroke risk in patients undergoing noncardiac and nonneurological procedures.

AHA Registry Provides Comprehensive Review of Ischemic Stroke in COVID-19 Patients

March 19, 2021

Using data from the AHA's COVID-19 Cardiovascular Disease Registry, a new analysis presented at ISC 21 provides an overview of the overall risk, risk factors, and outcomes of COVID-19-related ischemic stroke among US patients.

Immediate Angiography Could Preserve Function, Improve Outcomes in LVO Stroke

March 17, 2021

An interim analysis of the ANGIOCAT trial suggests immediate angiography could help preserve function and improve outcomes in the treatment of patients with stroke caused by a large vessel occlusion compared to the current standard of performing a CT scan.

Anticoagulant Use Among Afib Patients Wanes Over Time

November 18, 2015

ORLANDO -- Barely half of patients with atrial fibrillation who were prescribed rivaroxaban (Xarelto) to prevent stroke remained on the treatment after 2 years, but their adherence was still better than Afib patients on warfarin or dabigatran (Pradaxa), researchers said here.